Related Experiment Video
Updated: Mar 28, 2026
Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
Published on: February 25, 2016
Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics
Philippe Marchetti1, Pierre Guerreschi2, Laurent Mortier3
1Inserm UMR-S 1172, Faculté de Médecine, Université de Lille, 59045 Place Verdun Cedex, France ; Centre Hospitalier Régional et Universitaire (CHRU) de Lille, 5900 Lille, France.
Abstract:
Mitochondrial metabolism greatly influences cancer cell survival, invasion, metastasis, and resistance to many anticancer drugs. Furthermore, molecular-targeted therapies (e.g., oncogenic kinase inhibitors) create a dependence of surviving cells on mitochondrial metabolism. For these reasons, inhibition of mitochondrial metabolism represents promising therapeutic pathways in cancer. This review provides an overview of mitochondrial metabolism in cancer and discusses the limitations of mitochondrial inhibition for cancer treatment. Finally, we present preclinical evidence that mitochondrial inhibition could be associated with oncogenic "drivers" inhibitors, which may lead to innovative drug combinations for improving the efficacy of molecular-targeted therapy.
Insights
Targeting cancer cell mitochondrial metabolism offers new therapeutic avenues, especially when combined with molecular-targeted therapies. This approach may overcome drug resistance and improve treatment efficacy.
Area of Science:
- Oncology
- Cellular Metabolism
- Cancer Therapeutics
Background:
- Mitochondrial metabolism is crucial for cancer cell survival, invasion, metastasis, and drug resistance.
- Molecular-targeted therapies can increase cancer cell reliance on mitochondrial pathways.
- Inhibiting mitochondrial metabolism is a potential strategy for cancer treatment.
Purpose of the Study:
- To review the role of mitochondrial metabolism in cancer.
- To discuss the limitations of targeting mitochondrial metabolism.
- To explore the combination of mitochondrial inhibitors with molecular-targeted therapies.
Main Methods:
- Literature review of mitochondrial metabolism in cancer.
- Analysis of preclinical data on mitochondrial inhibition.
- Examination of drug resistance mechanisms.
Main Results:
- Mitochondrial metabolism significantly impacts cancer progression and therapy resistance.
- Targeting mitochondrial metabolism presents therapeutic opportunities but has limitations.
- Preclinical evidence suggests combining mitochondrial inhibitors with oncogenic driver inhibitors may enhance efficacy.
Conclusions:
- Mitochondrial metabolism is a key vulnerability in cancer.
- Overcoming limitations requires strategic therapeutic combinations.
- Novel drug combinations targeting mitochondrial metabolism and oncogenic pathways show promise for improving molecular-targeted therapy outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
01:39Mitochondrial Protein Sorting
Most of these mitochondrial proteins are encoded by the nucleus and imported to the mitochondria as unfolded or loosely folded precursors. Mitochondrial precursors...
01:19Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...